Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Sees Significant Drop in Short Interest

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) was the recipient of a significant drop in short interest in November. As of November 15th, there was short interest totalling 4,970,000 shares, a drop of 29.5% from the October 31st total of 7,050,000 shares. Based on an average daily volume of 2,060,000 shares, the days-to-cover ratio is presently 2.4 days.

Zentalis Pharmaceuticals Trading Down 0.6 %

NASDAQ ZNTL traded down $0.02 during midday trading on Friday, hitting $3.61. The company had a trading volume of 423,855 shares, compared to its average volume of 1,315,910. The company has a market capitalization of $257.25 million, a PE ratio of -1.48 and a beta of 1.74. Zentalis Pharmaceuticals has a twelve month low of $2.66 and a twelve month high of $18.07. The firm has a 50-day moving average price of $3.38 and a 200-day moving average price of $4.93.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.92) by $0.36. On average, equities analysts anticipate that Zentalis Pharmaceuticals will post -2.48 EPS for the current year.

Institutional Trading of Zentalis Pharmaceuticals

Large investors have recently made changes to their positions in the company. Values First Advisors Inc. lifted its stake in Zentalis Pharmaceuticals by 5.4% during the second quarter. Values First Advisors Inc. now owns 74,925 shares of the company's stock worth $306,000 after purchasing an additional 3,859 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Zentalis Pharmaceuticals by 63.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company's stock worth $50,000 after buying an additional 5,333 shares in the last quarter. Carson Advisory Inc. lifted its position in shares of Zentalis Pharmaceuticals by 55.8% during the 3rd quarter. Carson Advisory Inc. now owns 24,570 shares of the company's stock worth $90,000 after buying an additional 8,800 shares during the last quarter. Anfield Capital Management LLC acquired a new stake in Zentalis Pharmaceuticals in the second quarter valued at about $40,000. Finally, Erste Asset Management GmbH bought a new position in Zentalis Pharmaceuticals in the third quarter valued at about $37,000.

Wall Street Analysts Forecast Growth

ZNTL has been the subject of several analyst reports. Oppenheimer reissued an "outperform" rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a research note on Monday, September 16th. Guggenheim decreased their price objective on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a "buy" rating for the company in a research report on Friday, November 15th. Wedbush raised shares of Zentalis Pharmaceuticals from an "underperform" rating to a "neutral" rating and set a $4.00 target price on the stock in a report on Monday, August 12th. Finally, HC Wainwright reiterated a "buy" rating and set a $20.00 price target on shares of Zentalis Pharmaceuticals in a report on Friday, November 15th. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, Zentalis Pharmaceuticals presently has a consensus rating of "Hold" and a consensus price target of $10.00.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.